CNS Therapeutics Xchange
Europe 2022
zurich, november 24

Welcome to hubXchange’s Europe Hybrid CNS Therapeutics Xchange 2022, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing CNS therapies.
Discussion topics will cover Novel Targets, Preclinical, Clinical Studies and Drug Delivery.
Take advantage of this unique highly interactive meeting format designed for maximum engagement, collaboration and networking with your peers.

Please note this is an In-Person meeting. 

VENUE DETAILS: Hilton Zurich Airport Hotel, Hohenbuehlstrasse 10 – 8152 Opfikon, Switzerland

Novel Targets

Titles and Bullets
8:00 – 8:30am

8:30 – 9:00am

Opening Address & Keynote:


9:05 – 10:05am

Opportunities from emerging therapeutic modalities: Target selection in an evolving druggability landscape

  • Choosing the “Right candidate” target gene, with understanding of the disease with implications of modulation in CNS.
  • Drug testing using disease relevant model system that shows not just a part but as close to human disease phenotype.
  • Drug delivery approaches
  • Efforts on choosing the appropriate biomarker for preclinical and clinical evaluation.

Senior Research Scientist, AstraZeneca

10:10 – 10:40am
1-2-1 Meetings/Networking Break
10:40 – 11:10am
1-2-1 Meetings / Networking Break
11:10 – 11:20am
Morning Refreshments
12:20 – 1:20pm

Networking Lunch

1:20 – 1:50pm

Spotlight Presentation

1:55 – 2:55pm

Novel therapies for complex neurological disorders: discovery of effective treatments

  • What relevant novel CNS disorders and therapies are currently under development
  • What are novel trends in CNS disorder diagnostics and drug development?
  • How do you see the future for developing successful CNS therapies?

Senior Clinical Program Director Paediatrics-Neurology Patient Value Unit, UCB Biosciences GmbH

Frank Tennigkeit is a Drug Development Expert with more than 25 years of experience in the life sciences including more than 15 years of pharmaceutical industry/biotech experience.
His medical background comes from Pharmacology and Neuroscience. He has strong experience in clinical development and real world evidence generation, especially in Neurology (Alzheimer’s Disease, Epilepsy, Parkinson’s Disease and PSP) and orphan autoimmune disorders.
Currently he works for UCB Biosciences as Pediatric Development expert (pediatric development plans, PIPs, PSPs and indication expansions). He has also been Medical/Clinical Team Lead and manager of cross-functional teams.
He has extensive experience in planning, executing, publishing and submitting clinical development programs for leading to NDAs, submissions and successful drug approvals (US, EU, J, CN).

Frank Tennigkeit
3:00– 3:30pm
1-2-1 Meetings / Networking Break
3:30 – 4:00pm
1-2-1 Meetings / Networking Break
4:00 – 4:10pm
Afternoon Refreshments

4:10 – 4:40pm

Poster Session

4:45– 5:45pm


Principal Scientist, reMYND

5:45 – 6:45pm
Evening Drinks Reception


CNS Therapeutics Xchange | Europe 2022